Navigation Links
Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
Date:11/5/2007

e lipid peroxides and have the potential to limit myocardial damage subsequent to a myocardial infarction. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment, using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes.

Synvista Therapeutics also is developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database. For more information, please visit the Company's website at http://www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2006. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may di
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)...  Mobility Ventures LLC, an AM General Company, is ... (NYSE: BAC ) that will make it ... revolutionary MV-1 - - the world,s first and only ... provide safe and comfortable transportation for all passengers including ... purchase a new MV-1 vehicle at the over 150 ...
(Date:2/26/2015)... 26, 2015 LifeScienceIndustryResearch.com adds ... -In- Class Innovations and Cost Optimization Plays Major ... Pharmaceutical Companies research report to the pharmaceuticals intelligence ... this Global Pharma US & EU Outlook 2015 ... divestment of non-core assets result in healthy cash ...
(Date:2/26/2015)... , Feb. 26, 2015  Spring Bank Pharmaceuticals, ... for the treatment of virus infections, today announced ... been appointed Vice President of Finance, a newly ... financial and administrative activities, including financial planning and ... Douglas J. Jensen , President and CEO. ...
Breaking Medicine Technology:Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3Global Pharma U.S. and EU Outlook 2015 Market Research Report 2Global Pharma U.S. and EU Outlook 2015 Market Research Report 3Global Pharma U.S. and EU Outlook 2015 Market Research Report 4Jonathan P. Freve, CPA, Joins Spring Bank Pharmaceuticals as Vice President of Finance 2
... Cempra Pharmaceuticals announced that Carl Foster has been ... Foster will be focusing on business development activities ... the next-generation fluoroketolide solithromycin (CEM-101), that is in ... (CABP), and TAKSTATM (CEM-102 or fusidic acid), that ...
... 2011 Carbylan BioSurgery, Inc. announced today the completion ... trial to evaluate the safety and effectiveness of two ... in patients with osteoarthritis of the knee.   Hydros ... combination products. "Hydros and Hydros TA are ...
Cached Medicine Technology:Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development 2Carbylan BioSurgery Completes Enrollment in Key Clinical Feasibility Study of Hydros and Hydros TA in Patients With Pain From Knee Osteoarthritis; Core Patent Issued 2Carbylan BioSurgery Completes Enrollment in Key Clinical Feasibility Study of Hydros and Hydros TA in Patients With Pain From Knee Osteoarthritis; Core Patent Issued 3
(Date:2/26/2015)... IL (PRWEB) February 26, 2015 Thousands ... small step to fund powerful progress for the Muscular ... by raising critical funds and awareness that will help ... fighting muscle disease. , “MDA Muscle Walk events unite ... for people whose abilities to move are compromised — ...
(Date:2/26/2015)... SpendWell Health, an online marketplace for ... first customer today, opening its doors to Cambia ... , SpendWell delivers the next generation of online ... transparency with e-commerce. SpendWell’s unique platform shows actual ... services and allows shoppers to buy those services ...
(Date:2/26/2015)... a nested-case control study of individuals living in the UK, ... of liver cancer, statin use is associated with a decreased ... published February 26 in the JNCI: Journal of the ... association but most used data from individuals living in regions ... Katherine A. McGlynn, Ph.D., from the Division of Cancer Epidemiology ...
(Date:2/26/2015)... NJ (PRWEB) February 26, 2015 The ... reopening of their newly renovated office in Lawrenceville, NJ. ... Reproductive Science Center of New Jersey’s physicians, and NJ ... and patient care in the areas of infertility and ... for having excellent success rates and providing current, high ...
(Date:2/26/2015)... The hip resurfacing procedure at ... Texas resident John Short to resume his active lifestyle, it ... to climb Mt. Kilimanjaro, the highest free-standing mountain in the ... Starting in his late 20s, Short suffered from early onset ... and sockets were bone on bone. , Then about ...
Breaking Medicine News(10 mins):Health News:MDA Kicks-Off Annual Muscle Walk Season in Local Communities Nationwide to Fight Back Against Muscle Disease 2Health News:MDA Kicks-Off Annual Muscle Walk Season in Local Communities Nationwide to Fight Back Against Muscle Disease 3Health News:SpendWell Launches New Online Health Care Marketplace to Large Employer Group 2Health News:SpendWell Launches New Online Health Care Marketplace to Large Employer Group 3Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 2Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 3Health News:Hip Resurfacing at Texas Orthopedics Enables Patient to Climb Mt. Kilimanjaro 2Health News:Hip Resurfacing at Texas Orthopedics Enables Patient to Climb Mt. Kilimanjaro 3
... that break down pollutants do their job and then ... wastes. Research was conducted on those bacteria by cornell ... ethenogenes, discovered in Ithaca sewage sludge in 1997 by ... and isolated and studied by Stephen Zinder, Cornell professor ...
... wine halved in France since the 1950s, the world's number ... its saviour. But while the Chinese and Indians have ... worlds largest, there are those attending the two-yearly event who ... margins in China are not there. It is not ready ...
... New England Journal of Medicine,treating hepatitis B patients with the ... with HIV to become resistant to two of the most ... researchers reported that a patient infected with both hepatitis B ... strain of HIV that is resistant to the antiviral drugs ...
... first human trial of a locally-made H5N1 bird flu vaccine as ... officials in the communist country. The drug trial, to be ... of several global efforts to develop a vaccine for mass production, ... Asia. ,The news comes as a new wave of ...
... Boffins at the Scripps Research Institute have found in ... pleiotrophin (PTN) plays in accelerating breast cancer . ... in breast cancer had not been clearly established, and ... to a better understanding of the molecular pathogenesis of ...
... prostitute might have led Hitler to orchestrate the genocidal ... ,Hitler might have contracted syphilis, which, possibly untreated, ... Jews and the mentally retarded. ,There is ... Dr Bassem Habeeb. ,Dr Habeeb said that ...
Cached Medicine News:Health News:Insilico Studies on Chlorine Eating Bacteria 2Health News:Go for Russia, Not China, Wine Experts Say 2Health News:Go for Russia, Not China, Wine Experts Say 3Health News:Challenges in Entecavir Drug Treatment 2Health News:Vietnam Plans Human Trial of Bird Flu Vaccine 2Health News:Researchers Have Found the Role of Protein in Accelerating Breast Cancer Progression 2Health News:Researchers Have Found the Role of Protein in Accelerating Breast Cancer Progression 3Health News:Hitler's Holocaust may Have Stemmed from Syphilis from Jewish Prostitute 2
Inquire...
... intensity ,Smaller slot surface area results ... ,Small slot dimensions require less sample ... ,More intense signal generated with the slot-blotter allows ... Accepts all types of transfer membranes ...
... The Minifold I system consists of four basic ... plenum, and metal clamping plate (see diagram). The ... for producing spots, dots, or slots (see below). ... purchased as an accessory plate in conjunction with ...
... The Minifold I system consists of four ... vacuum plenum, and metal clamping plate (see diagram). ... configurations for producing spots, dots, or slots (see ... be purchased as an accessory plate in conjunction ...
Medicine Products: